Tetratherix Limited (ASX:TTX)

Tetratherix Limited, listed on ASX as TTX, has reported a strong cash position of AUD 34.4 million as of June 30, 2026, supported by a successful capital raise and license revenue. The company has achieved significant milestones in its Q4 FY26, including the advancement of its Tetramatrix™ platform for nasal drug delivery, with new patents obtained to strengthen its intellectual property. The construction of an advanced manufacturing facility in New South Wales is underway to meet global demand, with expected certification in CY26. Tetratherix is preparing for FDA clearances for its Tegenix and TegenEOS products, part of its Bone Regeneration franchise. The company also introduced a new ERP system to enhance manufacturing and operational efficiencies. Key financial inflows included a $15 million placement and a $4.2 million licence fee, enabling further growth and transition towards commercial scalability. The company is poised for a US market entry with its Tetramatrix™ platform branded as STEPP, following FDA regulatory clearances.